Gruppo Italiano Malattie EMatologiche dell'Adulto: Leukemia trials

The registry lists 66 Leukemia studies with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor. 9 are open to participants now and 7 have results posted.

Phase 1 4Phase 2 29Phase 3 3Phase 4 1No phase 31(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy of Gilteritinib in Combination With FLAI as Induction Therapy of FLT3-positive Acute Myeloid LeukemiaNot yet recruitingNCT06667973Phase 2
• Biological and Clinical Efficacy of Shingrix in Patients With CLLNot yet recruitingNCT06364033Not applicable
• Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease ProgressionNot yet recruitingNCT06084923
• Retrospective Observational Study on Infective Complications and Outcome of Patients With ALL Treated With INORecruitingNCT06025682
• Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.RecruitingNCT05803395
• Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
• Study on the Diagnosis and Management of CLL in Italy by GIMEMARecruitingNCT04867915
• Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALLRecruitingNCT04582487Not applicable
• Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid NeoplasmsRecruitingNCT04460950
• Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01403246Phase 1/2Results posted
• Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00775593Phase 2Results posted
• Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
• Vaccine Therapy in Treating Patients With Philadelphia Chromosome-Positive Chronic Myelogenous LeukemiaCompletedNCT00466726Phase 2Results posted
• Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic LeukemiaCompletedNCT00462332Phase 2Results posted
• Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic LeukemiaCompletedNCT00458848Phase 2Results posted
• Treatment of Adult Ph+ LAL With BMS-354825CompletedNCT00391989Phase 2Results posted
• Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid LeukemiaStatus unknownNCT04867928Phase 2
• Trial in AML Secondary to MPNs Patients, Unfit for Intensive Chemotherapy, Investigating a Treatment Combination Including Decitabine and VenetoclaxActive, not recruitingNCT04763928Phase 2
• Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
• Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL PatientsStatus unknownNCT04640909Not applicable
• Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological RelapseActive, not recruitingNCT04475731Phase 2
• Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid LeukemiaTerminatedNCT04342962Phase 2
• Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in ItalyActive, not recruitingNCT04282811
• The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir AlafenamideTerminatedNCT03804372Phase 2
• Long-term Outcomes for Acute Myeloid Leukemia PatientsStatus unknownNCT03755856
• Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic LeukemiaStatus unknownNCT03751917
• Asparaginase Activity Monitoring (AAM) in Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT03668392Phase 2
• Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL) Treated With Idelalisib and Rituximab in the Clinical Practice: a GIMEMA-ERIC StudyCompletedNCT03545035
• The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With IbrutinibCompletedNCT03528941
• Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic LeukemiaCompletedNCT03455517Phase 2
• Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)TerminatedNCT03410407
• Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic LeukemiaCompletedNCT03367299Phase 2
• Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaStatus unknownNCT03318770
• Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard ChemotherapyStatus unknownNCT03096496
• Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid LeukemiaStatus unknownNCT03075969
• Bosutinib in Elderly Chronic Myeloid LeukemiaCompletedNCT02810990Phase 2
• D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02744768Phase 2
• Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid LeukemiaStatus unknownNCT02602314Phase 4
• Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient ProgramCompletedNCT02582320
• Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic LeukemiaCompletedNCT02491398
• Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to ImatinibTerminatedNCT02398825Phase 2
• Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
• Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic LeukemiaCompletedNCT02232386Phase 2
• Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)CompletedNCT02185781Phase 1
• LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia PatientsStatus unknownNCT02164903
• MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted MethotrexateCompletedNCT02067143Phase 2
• Occupational Status and Hematological DiseaseCompletedNCT02057185
• Long-Term Quality of Life in Patients With Acute Promyelocytic LeukemiaCompletedNCT01910623
• Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.CompletedNCT01762202Phase 2
• Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With DasatinibStatus unknownNCT01761890
• Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase InhibitorsStatus unknownNCT01752062
• Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic PhaseCompletedNCT01699217
• Nilotinib in PH+, BCR-, ABL+ CML PatientsCompletedNCT01535391Phase 3
• Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With NilotinibCompletedNCT01475110
• Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With ChemotherapyCompletedNCT01472107
• Risk-adapted, MRD-directed Therapy for Young Adults With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01452646Phase 2
• Patient Reported Outcomes in Chronic Myeloid LeukemiaCompletedNCT01252589
• Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic LeukemiaCompletedNCT01156883Not applicable
• Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT01154439Phase 1
• AIDA 2000 GuidelinesStatus unknownNCT01064570Phase 2
• "AIDA" Protocol (LAP 0493)Status unknownNCT01064557Not applicable
• Mid-to Long-Term Outcomes in Chronic Myeloid Leukemia (CML) Patients With Complete Cytogenetic Response After Imatinib as First Line TherapyCompletedNCT00896129
• Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
• Phase III Trial in Acute Promyelocytic Leukemia PatientsCompletedNCT00482833Phase 3
• GIMEMA LAL 0496: High-dose Anthracycline in the Induction Regimen for the Treatment of Adult ALL.Status unknownNCT00439920Phase 2
• STI 571 (GLIVEC) in the Treatment of Adult Acute Lymphoblastic LeukemiaCompletedNCT00376467Phase 2